Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Prostate cancer
Phase 1b sipuleucel‑T + N‑803 trial tests PAP vaccine plus IL‑15 superagonist immunostimulation
Washington University School of Medicine is running a single-center, open-label Phase 1b, modified 3+3 de-escalation study to define safety, tolerability, and the recommended Phase 2 dose for combining sipuleucel‑T…
NCT07756593 Exploratory - New trial
Prostate cancer
Phase 2 BALANCE-RT compares HDR brachytherapy boost vs SBRT alone (radiation intensification).
Memorial Sloan Kettering Cancer Center is running BALANCE-RT (NCT07751159) to test whether adding an HDR brachytherapy boost (temporary internal radiation that delivers very high dose inside the prostate) to SBRT…
NCT07751159 Exploratory - New trial Spotlight
Breast cancer
Phase 2 pembrolizumab PD‑1 inhibitor with anthracycline-sparing neoadjuvant chemo in high‑TIL TNBC
This Phase 2 NeoTILs study from the Medical University of South Carolina (MUSC) tests a biomarker-guided de-escalation strategy in stage II–IIIB triple-negative or hormone receptor–low (ER/PR <10%) invasive breast…
NCT07743190 Exploratory - New trial
Breast cancer
Phase 2 partial breast irradiation (EBRT) trial tests localized radiation field to omit axillary staging
NYU Langone Health is running RADIANS (NCT07723209), a single-arm, prospective pilot evaluating the safety and longer-term regional control of partial breast irradiation (PBI) delivered with external beam radiation…
NCT07723209 Exploratory - New trial
Breast cancer
Phase 1b/2 asciminib allosteric BCR-ABL inhibitor + trastuzumab HER2 mAb in HER2+ BrM
Duke University is running ASCENdANT, a single-arm, open-label Phase 1b/2 study testing asciminib plus trastuzumab for patients with metastatic HER2-positive breast cancer with brain metastases, with the primary goal…
NCT07136428 Exploratory - New trial
Breast cancer
Phase 3 SRG-514 ketorolac COX-1/2 inhibitor hydrogel placed in lumpectomy cavity in TNBC
SURGE Therapeutics is running a randomized, blinded Phase 3 study testing SRG-514, a ketorolac (NSAID) hydrogel placed intraoperatively into the breast-conserving surgery resection cavity, versus breast-conserving…
NCT07723469 Registrational - New trial
Breast cancer
Phase 1b/2 BreakVax personalized neoantigen vaccine + PD-1 and CTLA-4 blockade immunotherapy
BreakBio Corp’s Phase 1b/2 study tests a multi-component regimen built around BreakVax, a per-patient manufactured personalized vaccine intended to prime tumor-specific T cells (a neoantigen peptide immunotherapy) in…
NCT07762703 Exploratory - New trial Spotlight
Small cell lung cancer
Phase 3 ABBV-706 SEZ6-targeted topo-1 ADC vs chemotherapy in R/R SCLC
AbbVie’s randomized, open-label Phase 3 trial tests ABBV-706 against physician’s-choice topotecan, lurbinectedin, or amrubicin in roughly 531 patients with relapsed/refractory SCLC. ABBV-706 is a SEZ6-directed…
NCT07365241 Registrational - New trial
Ovarian cancer
Phase 1b/2 TUB-040 NaPi2b-targeted topoisomerase I inhibitor (exatecan) ADC + Carbo/Bev
This multicenter Phase 1b/2 study evaluates TUB-040 (Tubulis GmbH)—a NaPi2b-directed antibody–drug conjugate delivering the topoisomerase I inhibitor payload exatecan via a cleavable linker—combined with carboplatin…
NCT07736937 Exploratory - New trial
Ovarian cancer
Phase 2 OVAFIT-TIL CD137 (4-1BB)–selected autologous TIL + PD-1 blockade
This Phase 2 study at the Medical University of South Carolina (MUSC) tests an autologous tumor-infiltrating lymphocyte (TIL) product that is metabolically optimized and enriched for CD137+ (4-1BB+) activated T…
NCT07720180 Exploratory - New trial Spotlight
Ovarian cancer
Phase 1 ARR-002 dual-target MUC16/NaPi2b ADC (vcMMAE microtubule inhibitor payload) in ovarian/endometrial cancer.
This first-in-human, open-label, multicenter Phase 1a/1b dose-escalation/expansion study evaluates ARR-002 in adults with locally advanced or metastatic ovarian or endometrial cancer. ARR-002 (ArriVent BioPharma) is…
NCT07755436 First-in-human - New trial Spotlight
Kidney cancer
Phase 3 belzutifan HIF-2α inhibitor + zanzalintinib multi-kinase VEGFR/c-MET inhibitor in advanced RCC.
Merck Sharp & Dohme (MSD) is running LITESPARK-034 (MK-6482-034), a Phase 3 randomized, double-blind study testing belzutifan plus zanzalintinib versus belzutifan plus placebo in advanced/unresectable renal cell…
NCT07489495 Registrational - New trial
Kidney cancer
Phase 1/2 mercaptopurine (6‑MP) purine antagonist (DNA synthesis inhibitor) in HLRCC
This Phase 1/2, open-label, multi-cohort study evaluates oral mercaptopurine (6‑MP), a thiopurine antimetabolite/purine antagonist that disrupts DNA/RNA synthesis after intracellular activation, to define safety,…
NCT07716735 Exploratory - New trial
Kidney cancer
Phase 1 casdatifan selective HIF-2α transcription-factor inhibitor pilot in refractory ccRCC
Vanderbilt-Ingram Cancer Center is running a single-institution, open-label pilot study of oral casdatifan (AB521), a small-molecule, allosteric inhibitor of HIF-2α–dependent transcription, in metastatic clear cell…
NCT07748988 Exploratory - New trial
Non-small cell lung cancer
Phase 2 SBRT “hot spot” dose-painting radiotherapy to intensify tumor hotspots in early NSCLC.
Roswell Park Cancer Institute is running PRESTO, a randomized Phase 2 trial testing whether intentionally creating higher-dose “hot spots” inside the tumor during stereotactic ablative radiotherapy (SABR/SBRT)—a…
NCT07718672 Exploratory - New trial
Brain and CNS tumors
Phase 1b/2 BreakVax personalized vaccine + PD-1/CTLA-4 checkpoint blockade in GBM
This Phase 1b/2, multicenter, open-label, single-arm study in adults with glioblastoma (GBM) tests a multi-component immunotherapy strategy anchored by BreakVax (BB-101), a per-patient designed/manufactured…
NCT07762716 Exploratory - New trial
Liver and bile duct cancer
Phase 2 durvalumab PD-L1 inhibitor plus histotripsy non-thermal focused ultrasound ablation in iCCA
This single-group Phase 2 pilot study (CODAH) at the University of Wisconsin–Madison evaluates whether adding histotripsy to ongoing maintenance durvalumab increases anti-tumor immune activation and remains safe in…
NCT07766187 Exploratory - New trial
Melanoma
Phase 2 NASA tests pembrolizumab PD‑1 blockade vs ipilimumab CTLA‑4 + nivolumab PD‑1 in resectable melanoma.
This randomized Phase 2 study at UNC Lineberger Comprehensive Cancer Center asks whether a short neoadjuvant checkpoint regimen can safely replace the usual months-long postoperative (adjuvant) systemic therapy in…
NCT07740941 Exploratory - New trial
Colorectal cancer
Phase 2 S-531011 CCR8-directed monoclonal antibody plus RadScopal radiation in MSS mCRC.
This Phase 2 MD Anderson Cancer Center study tests whether S-531011 (a CCR8-directed monoclonal antibody designed to modulate CCR8+ immune cells in the tumor microenvironment) can work better when paired with…
NCT07720115 Exploratory - New trial
Multiple solid tumors
Phase 1 SLR-108 PTK7-targeted antibody–radionuclide conjugate for immuno-PET imaging.
This Phase 1, interventional, open-label imaging study from Solve Therapeutics is testing whether SLR-108 can feasibly visualize metastatic solid tumors on PET after a single IV administration. SLR-108 is a…
NCT07728942 Exploratory - Trial result
Non-small cell lung cancer
Nivolumab/ipilimumab-based regimens lift 5-year survival in PD-L1–negative Japanese mNSCLC
Nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor), given first-line with or without 2 cycles of chemotherapy (CheckMate 227/9LA pooled), was analyzed in Japanese patients with metastatic NSCLC, PD-L1 <1%,…
- Trial result
Non-small cell lung cancer
Nivolumab (PD-1 blockade) + chemo: ctDNA clearance flags higher pCR and longer EFS in resectable NSCLC
Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor, was evaluated as perioperative therapy in the Phase 3, double-blind CheckMate 77T trial (NCT04025879): neoadjuvant nivolumab + platinum-doublet chemotherapy (4…
NCT04025879 - Trial result
Stomach and esophageal cancer
Nivolumab (PD-1) + chemo or nivolumab + ipilimumab (CTLA-4) sustains OS benefit at 5 years in 1L advanced ESCC
Nivolumab, a PD-1 checkpoint inhibitor, combined with platinum/fluoropyrimidine chemotherapy—or paired with ipilimumab (CTLA-4)—was evaluated versus chemotherapy alone in the open-label Phase 3 CheckMate 648 trial…
NCT03143153 - Trial result
Colorectal cancer
mFOLFOX6/Bevacizumab + Atezolizumab (PD-L1) Extends PFS vs Atezolizumab Alone in 1L dMMR/MSI-H mCRC
NRG-GI004/SWOG S1610 (COMMIT; Phase III, open-label) randomized patients with previously untreated dMMR/MSI-H metastatic colorectal cancer to atezolizumab (PD-L1 antibody) monotherapy vs mFOLFOX6 + bevacizumab (VEGF…
- Trial result Spotlight
Melanoma
Spartalizumab (PD-1) + Dabrafenib/Trametinib Extends OS vs BRAF/MEK Alone in BRAF V600 Melanoma
Spartalizumab is an anti–PD-1 monoclonal antibody combined here with dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) as first-line targeted therapy intensification for BRAF V600-mutant…
NCT02967692 - Trial result Spotlight
Prostate cancer
Olaparib (PARP inhibitor) + Abiraterone Shows BRCA2-Driven Benefit in 1L mCRPC
Olaparib is an oral PARP inhibitor combined here with abiraterone, a CYP17 androgen-biosynthesis inhibitor, plus prednisone/prednisolone in the randomized, double-blind Phase 3 PROpel trial (NCT03732820) in…
NCT03732820 - Trial result
Prostate cancer
NRG-GU005: 5-fraction SBRT improves bowel QOL but does not improve 3-year DFS vs MH-IMRT.
SBRT is an ultra-hypofractionated, image-guided radiotherapy regimen (36.25Gy/5 fractions) compared head-to-head with moderately hypofractionated IMRT (70Gy/28 or 60Gy/20) in the Phase 3, international, open-label…
NCT03367702 - Trial result
Prostate cancer
Darolutamide (AR antagonist) + ADT cuts rPFS risk across high- and low-volume mHSPC in ARANOTE
Darolutamide is an oral androgen-receptor inhibitor evaluated with androgen-deprivation therapy (ADT) vs placebo + ADT in the Phase 3 ARANOTE trial (NCT04736199) in metastatic hormone-sensitive prostate cancer…
NCT04736199 - Trial result
Head and neck cancer
TPF induction (docetaxel/cisplatin/5-FU) fails to beat PF adjuvant after CCRT in LA-NPC, with more myelosuppression
TPF is a taxane–platinum–fluoropyrimidine triplet induction chemotherapy regimen given pre-radiation, while PF (cisplatin/5-fluorouracil) is a platinum–fluoropyrimidine doublet commonly used in older…
NCT03574324 - Trial result
Myeloproliferative neoplasms
Ruxolitinib (JAK1/2 inhibitor) Loses SVR35/TSS50 Ground When Early Cytopenias Emerge in MF
Ruxolitinib is an oral JAK1/2 inhibitor approved for myelofibrosis (MF), but dose intensity is often constrained by anemia and thrombocytopenia. In this post hoc analysis of the Phase 3 SIMPLIFY-1 trial…
NCT01969838
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.